An additive interaction between the NF kappa B and estrogen receptor signalling pathways in human endometrial epithelial cells

Citation for published version:

Digital Object Identifier (DOI):
10.1093/humrep/dep421

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Human Reproduction

Publisher Rights Statement:
© The Author 2009. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
An additive interaction between the NFκB and estrogen receptor signalling pathways in human endometrial epithelial cells

A.E. King¹, F. Collins², T. Klonisch³, J.-M. Sallenave⁴,⁵, H.O.D. Critchley¹, and P.T.K. Saunders²,⁶

¹Reproductive & Developmental Sciences, University of Edinburgh, Edinburgh, UK ²Medical Research Council Human Reproductive Sciences Unit, Centre for Reproductive Biology, The Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK ³Department of Human Anatomy & Cell Science, University of Manitoba, Winnipeg, Canada ⁴Universite Denis Diderot, Paris 7, France ⁵Unite de Defense Innee et Inflammation, INSERM U874, Batiment Metchnikoff, Institut Pasteur, 25, rue du Dr Roux, 75724 Paris Cedex, France ⁶Correspondence address. Tel: +44-131-242-9100; Fax: +44-131-242-6197; E-mail: p.saunders@hrsu.mrc.ac.uk

BACKGROUND: Human embryo implantation is regulated by estradiol (E2), progesterone and locally produced mediators including interleukin-1β (IL-1β). Interactions between the estrogen receptor (ER) and NF kappa B (NFκB) signalling pathways have been reported in other systems but have not been detailed in human endometrium.

METHODS AND RESULTS: Real-time PCR showed that mRNA for the p65 and p105 NFκB subunits is maximally expressed in endometrium from the putative implantation window. Both subunits are localized in the endometrial epithelium throughout the menstrual cycle. Reporter assays for estrogen response element (ERE) activity were used to examine functional interactions between ER and NFκB in telomerase immortalized endometrial epithelial cells (TERT-EECs). E2 and IL-1β treatment of TERT-EECs enhances ERE activity by a NFκB and ER dependent mechanism; this effect could be mediated by ERα or ERβ. E2 and IL-1β also positively interact to increase endogenous gene expression of prostaglandin E synthase and c-myc. This is a gene-dependent action as there is no additive effect on cyclin D1 or progesterone receptor expression.

CONCLUSION: In summary, we have established that NFκB signalling proteins are expressed in normal endometrium and report that IL-1β can enhance the actions of E2 in a cell line derived from healthy endometrium. This mechanism may allow IL-1β, possibly from the developing embryo, to modulate the function of the endometrial epithelium to promote successful implantation, for example by regulating prostaglandin production. Aberrations in the interaction between the ER and NFκB signalling pathways may have a negative impact on implantation contributing to pathologies such as early pregnancy loss and infertility.

Key words: NFκB / estrogen receptor / endometrial epithelium / implantation

Introduction

The human endometrium is a dynamic tissue that undergoes cycles of proliferation, differentiation, breakdown and repair (Jabbour et al., 2006; van Mourik et al., 2009). The development of the endometrium in preparation for implantation of the fertilized conceptus is under the control of the sex steroid hormones, estradiol and progesterone. Implantation occurs during the mid-late secretory phase of the menstrual cycle (the ‘implantation window’) and is characterized as an inflammatory event associated with increased expression of inflammatory mediators and immune cell infiltration (van Mourik et al., 2009). The actions of estrogens on the endometrium are mediated by estrogen receptors (ER)α and ERβ both of which are expressed in epithelial and stromal cells (Critchley et al., 2001, 2002; Critchley and Saunders 2009). Immunoexpression of ERα varies during the normal cycle with intense staining in epithelial and stromal cells during the proliferative phase but a marked reduction in the functional layer during the late secretory phase (Lessey et al., 1988; Critchley et al., 2001). In contrast, ERβ alone is expressed in both endothelial and uterine natural killer cells (Henderson et al., 2003) and appears similar in epithelial and stromal cells during both the proliferative and secretory phases (Critchley et al., 2002). As a result ERβ appears to be the
predominant isoform in both the glandular (Critchley et al., 2002) and surface (Bombail et al., 2008) epithelium during the implantation window.

Inflammatory events including immune cell infiltration can be mediated via activation of NF kappa B (NfkB)-dependent gene transcription. NfkB is a dimeric transcription factor consisting of homo- or hetero-dimeric complexes of the Rel family of proteins; in the inactive state the complex is sequestered in the cytoplasm by a family of endogenous inhibitors, called IκBs. Previous studies have reported that expression of the NfkB subunits, p65 (Rel A) and p50, are increased during the mid secretory phase (Laird et al., 2000; Page et al., 2002) although expression of IκBα is reported to fall at this time (Page et al., 2002). These semi-quantitative immunohistochemical studies would be consistent with a role for NfkB activation during the implantation window. However, this has not been confirmed using quantitative analysis.

Estrogens are well documented as having anti-inflammatory effects whereas activated NfkB initiates and maintains cellular inflammatory responses (Biswas et al., 2005; Harnish, 2006). Evidence for the anti-inflammatory effects of estrogens was highlighted by the observation that pregnancy reduces the symptoms of rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease (Harnish, 2006). One mechanism by which estrogens can modulate inflammatory events has been described in articles documenting that reciprocal inhibitory cross-talk exists between NfkB and ER both in vitro (Harnish et al., 2000; Feldman et al., 2007; Quaedackers et al., 2007) and in vivo (Evans et al., 2001). For example, direct interactions between ERα and p65 (Quaedackers et al., 2007), as well as cofactor involvement and modulation of IκBα expression by E2 (Nakshatri et al., 1997; Sun et al., 1998) have been reported. However, more recent studies have also reported that a positive interaction between NfkB and ER signalling can occur. For example, Adamson et al. (2008) found that treatment with E2 plus TNFα had a synergistic effect on estrogen response element (ERE)-dependent activation of the human prolactin gene in GH3 pituitary cells. Similarly, proinflammatory cytokines (TNFα, IL-1β or IL-6) and E2 also act synergistically to up-regulate expression of prostaglandin E synthase (PGES) mRNA levels in MCF7 breast cancer cells (Frasor et al., 2008). As inflammation and steroid hormone action both play critical roles in endometrial function, we aimed to investigate whether cross-talk between NfkB and ER signalling occurs in endometrial epithelial cells and whether this is inhibitory or stimulatory in nature.

**Materials and Methods**

**Patients and tissue collection**

Endometrial samples (n = 24) was collected from women undergoing procedures for benign gynaecological conditions. All women had regular menstrual cycles and had not undergone hormonal treatment in the 3 months preceding biopsy. Histological dating of the samples was performed according to the criteria of Noyes (1950). Serum samples collected at the time of endometrial biopsy were used for determination of circulating estradiol and progesterone concentrations by radioimmunoassay (Table I). These circulating steroid hormone levels were consistent with the histological assessment that was undertaken by an expert histologist. Tissues were either fixed in 4% neutral buffered formalin overnight at 4°C and embedded in paraffin wax according to standard procedures or placed in RNA Later (Ambion/Applied Biosystems, Warrington, UK) for subsequent RNA extraction. Written informed consent was obtained from all patients and ethical approval was granted by the Lothian research ethics committee.

**Cell culture**

Telomerase immortalized endometrial epithelial cells (TERT-ECC) were originally derived from normal endometrium obtained during the proliferative phase. These cells express ERα, ERβ and PR mRNA and protein (Hombach-Klonisch et al., 2005; Collins, unpublished). Cells were seeded in 24 well culture plates (Coming-Costar) at a density of 1 × 10^4/ well in Hams F-10 medium supplemented with 10% charcoal stripped fetal calf serum (Sigma, Dorset, UK), insulin—transferrin—selenium (ITS, 1×; Lonza, Slough, UK), penicillin/streptomycin and gentamycin (Sigma). Ishikawa cells (ECACC, Salisbury, UK) were originally derived from the endometrial adenocarcinoma from a 39-year-old woman (Nishida et al., 1985). In our hands, this line of Ishikawa cells expresses ERα, ERβ and PR; cells were seeded in 24 well culture plates at a density of 1 × 10^5/ well in DMEM medium supplemented with 10% charcoal stripped fetal calf serum, i-glutamine, penicillin/streptomycin and non-essential amino acids (1%).

**Luciferase reporter assays**

An adenoviral vector containing a 3xERE-tk-luciferase reporter gene was prepared by subcloning a piece of DNA containing the ERE promoter and luciferase sequences from a plasmid that was a kind gift from Professor DP McDonnell [(Hall and McDonnell, 1999), Duke University NC, USA] into the adenoviral genome (pBHGLoxΔE1,3Cre, Microbix) that was propagated in Hek293 cells according to standard methods. An adenosivirus containing an NfkB response element linked to a luciferase reporter gene was obtained from Vector BioLabs (Philadelphia, USA). The control adenosirus (Ad-d1703) and an adenosivirus containing a dominant negative IκBα mutant (Ad-IκBα) have been described previously (Jobin et al., 1997; Henriksen et al., 2004). Luciferase was detected using the Bright-Glo luciferase assay system (Promega, Southampton, UK) as detailed in the manufacturer’s instructions.

Three separate experimental protocols were used to examine the effects of E2 and IL-1β on ER activity in TERT-ECC. In all experiments, cells were infected with adenosirus containing the ERE-luc expression construct. The total multiplicity of infection (MOI) was 100.

(i) Cells were left untreated or treated with the ER antagonist, ICI 182720 (10^{-6} M), for 1 h. Thereafter cells were either left untreated or incubated with vehicle (DMSO), E2 (10^{-8} M), IL-1β (0.1 ng/ml) or E2 + IL-1β for a further 24 h.

(ii) Cells were co-infected with a control adenosirus (Ad-d1703) or an adenosivirus containing a dominant negative IκBα mutant (Ad-IκBα) at a total MOI of 100. The following day, cells were either left untreated or treated with vehicle (DMSO), E2 (10^{-8} M; Sigma), IL-1β (0.1 ng/ml; Peprotech, London, UK) or E2 + IL-1β and incubated for a further 24 h.

(iii) Cells were co-infected with a control adenosirus (Ad-d1703) or an adenosivirus containing a dominant negative IκBα mutant (Ad-IκBα) at a total MOI of 100. Cells were either left untreated or treated with vehicle (DMSO), IL-1β (0.1 ng/ml), the ERα selective agonist, PPT (4,4′-4-(4-propyl-1H)-pyrazole-1,3,5-triyl) tris-phenol (Kraichely et al., 2000)) at 10^{-7} M, the ERβ selective agonist, DPN (2,3-bis(4-hydroxyphenyl)-propionitrile (Meyers et al., 2001)) at 10^{-2} M, or combinations of these treatments (PPT + IL-1β or DPN + IL-1β) and incubated for 24 h.
Concentrations of E2, PPT and DPN used were those found to give an optimal response in the ERE reporter assay in pilot studies. In additional complementary experiments, Ishikawa cells were infected with ERE and either Ad-d1703 or Ad-IkBx (total MOI = 50) and treated as in (i).

The impact of treatments on NFkB signalling was investigated by infecting TERT-EECs with the NFkB-luc reporter at an MOI of 50; cells were treated with vehicle, E2 (10⁻⁸ M), IL-1β (0.1 ng/ml) or E2 + IL-1β for 24 h. Each experiment was repeated on three separate occasions.

### Table 1 Details of endometrial biopsies

<table>
<thead>
<tr>
<th>Cycle phase</th>
<th>Number of samples</th>
<th>E2 (pM), range median</th>
<th>P4 (nM), range median</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROL</td>
<td>7</td>
<td>78.91–559.09, 31.1</td>
<td>0.97–5.91, 2.47</td>
</tr>
<tr>
<td>ES</td>
<td>5</td>
<td>289–599, 0.12, 504.3</td>
<td>5.5–112.9, 80.5</td>
</tr>
<tr>
<td>MS</td>
<td>6</td>
<td>279–1949, 659.2</td>
<td>42.10–114.53, 78.6</td>
</tr>
<tr>
<td>LS</td>
<td>4</td>
<td>59.09–819, 172.1</td>
<td>1.06–11.29, 5.4</td>
</tr>
<tr>
<td>MENST</td>
<td>2</td>
<td>371, 223</td>
<td>7.54, 2.98</td>
</tr>
</tbody>
</table>

Cycle phase (as determined by the Noyes’ criteria) was consistent with circulating estradiol and progesterone concentrations at time of biopsy. PROL = proliferative; ES, MS and LS = early, mid and late secretory; MENST = menstrual.

### Statistics

Significant differences in mRNA expression in endometrial biopsies was determined by one-way ANOVA and Tukey’s post hoc analysis. These data were logarithmically transformed prior to statistical analysis. Data from reporter assays were statistically analysed using repeated measures two-way ANOVA and Bonferroni’s post hoc analysis. Vehicle treatments are not shown in figures as there was no statistical difference between vehicle and control (without vehicle) samples in any of the experiments. Fold changes quoted in the results section were calculated by comparison to the untreated control for IL-1β and by comparison to DMSO (vehicle control) for E2 and E2 + IL-1β. Significant differences in mRNA expression in cell culture experiments were determined using repeated measures two-way ANOVA and Bonferroni’s post hoc analysis.

### Results

Expression of p65 and p105 mRNA in endometrium is highest during the secretory phase of the menstrual cycle

Quantitative RT–PCR analysis of well characterized endometrial biopsies showed that p65 mRNA expression is highest during the mid and late secretory phases (Fig. 1A; P < 0.05). p105 mRNA expression peaks during the late secretory phase of the menstrual cycle (Fig. 1B; P < 0.05).

p65, p105/p50 and IκBα are widely expressed in the human endometrium and are present in both epithelial and stromal compartments

Immunohistochemical localization of p65, p105/p50 and IκBα was performed on endometrial (n = 17) sections as follows. Antigen retrieval was carried out using a microwave (15 min in antigen unmasking solution, Vector, Peterborough, UK); endogenous peroxidase activity was blocked with 3% hydrogen peroxide (Sigma-Aldrich, Dorset, UK). Additional pre-treatments involved incubation with solutions from the avidin biotin blocking kit (Vector) and the DakoCytomation protein block (Dako, Ely, UK), 10 min each at room temperature. Sections were incubated overnight at 4°C with either rabbit-anti p65 (1:500; Santa Cruz), rabbit anti-p105/50 (1:500; NLS, Santa Cruz) or rabbit anti-IκBα (1:300; E130, Abcam, Cambridge, UK) diluted in REAL antibody diluent (Dako). For negative controls, the primary antibody was substituted with antibody diluent alone. Sections were washed and incubated with a biotinylated goat anti-rabbit secondary antibody and the avidin biotin peroxidase detection system, both for 30 min at room temperature (Vectorstain Elite ABC, Vector). Positive staining was detected using diaminobenzidine (ImmPACT DAB; Vector) and sections were counterstained with Harris’ haematoxylin.
IL-1β and E2 interact to enhance ERE-dependent reporter gene activity in endometrial epithelial cells and this is ER dependent

Initial studies conducted using endometrial adenocarcinoma Ishikawa cells showed that treatment with E2 raised ERE activity 4-fold whereas addition of IL-1β alone or in combination with E2 had no impact on reporter gene activity (Supplementary data, Fig. S1; \( P \leq 0.01 \)).

Incubation of TERT-EECs with \( 10^{-8} \) M E2 resulted in a 5-fold increase in the ERE-dependent expression of luciferase (Fig. 3). In contrast with the Ishikawa cells, increased expression was also observed when cells were treated with IL-1β alone and simultaneous exposure to E2 and IL-1β increased ERE-luciferase reporter activity 15-fold (Fig. 3; \( P < 0.01 \)). Both basal ERE activity and the increased ERE activity that occurred when TERT-EEC were treated with E2, IL-1β or E2+IL-1β were abolished by the presence of the ER antagonist, ICI 182720.

In complementary studies, NFκB response element activity was increased when TERT-EEC were incubated with IL-1β alone. However, incubation with E2 had no impact on expression of the luciferase reporter and there was no evidence of an additive or synergistic effect when cells were co-incubated with E2 and IL-1β (data not shown).

Activation of ERE-dependent reporter gene activity by IL-1β is NFκB-dependent and the interaction between NFκB and ER signalling pathways may be mediated by either ERα or ERβ

In a similar experiment assessing ERE activation, the presence of a dominant negative IκBα molecule reduced IL-1β-dependent increases

Figure 1 Differential mRNA expression of p65 and p105 in endometrium from throughout the menstrual cycle.

\( P = \) proliferative; ES = early secretory; MS = mid secretory; LS = late secretory. Same letters denote statistical significance. (A) p65. p65 mRNA expression is maximal during the mid and late secretory phase of the menstrual cycle. ab: \( P < 0.05 \) (B) p105. p105 mRNA expression peaks in the late secretory of the menstrual cycle. a: \( P < 0.05 \).

Figure 2 Immunolocalization of p65, p105/p50 and IκBα in endometrium from the mid secretory phase of the menstrual cycle.

There were no obvious changes in the pattern of localization in endometrial biopsies from across the menstrual cycle. The pattern of localization is demonstrated in a representative endometrial biopsy from the mid secretory phase. (A) p65. (B) p50. (C) IκBα. Negative controls in insets. Scale bar = 100 μm. ep = epithelium; s = stroma; e = endothelium.
in ERE-luciferase gene expression when cells were incubated with IL-1β alone or IL-1β plus E2 (Fig. 4A).

Treatment of TERT-ECC with the ERα selective agonist, PPT, or the ERβ selective agonist, DPN, increased ERE-luciferase reporter gene expression 5-fold and 4-fold, respectively. When the cells were treated with IL-1β in combination with PPT or DPN, ERE activity was raised 13-fold and 12-fold, respectively (Fig. 4B; $P < 0.001$), and these additive interactions were reduced by the presence of Ad-IκBα.

**IL-1β and E2 act additively to enhance expression of PGES and c-myc**

Expression of PR$_{A1+B}$, c-myc, PGES and cyclin D1 in TERT-ECC was examined after 2, 4 and 8 h of treatment. PR$_{A1+B}$ mRNA expression was significantly increased by treatment with E2 at 4 and 8 h and this was unaffected by treatment with IL-1β (Fig. 5A; $P < 0.05$). c-myc mRNA expression was up-regulated 3.4-fold by treatment with E2 alone at 8 h and this increase was enhanced in the presence of IL-1β (6.7-fold increase, Fig. 5B; $P < 0.05$). Treatment with IL-1β alone did not alter c-myc mRNA expression. Expression of PGES mRNA in TERT-ECC was increased 2.7-fold and 4.8-fold by treatment with E2 and IL-1β for 8 h, respectively. E2 and IL-1β acted together to raise PGES mRNA expression by 9.5-fold (Fig. 5C; $P < 0.001$). Similar effects of treatment were observed at 4 h. In contrast, cyclin D1 mRNA expression was increased 1.6-fold by treatment with E2 at 8 h and this response was not altered by the presence of IL-1β (Fig. 5D; $P < 0.01$).

**Discussion**

To our knowledge, we report novel data detailing an additive interaction between the ER and NFκB signalling pathways in endometrial epithelial cells derived from normal healthy endometrium (Hombach-Klonisch et al., 2005). The increase in ERE activity could be mediated by either ERα or ERβ.

Previous studies have reported negative interactions between the ER and NFκB pathways. Mutual repression of signalling between NFκB and ER has been reported in various in-vitro systems (Harnish et al., 2000; Feldman et al., 2007; Quaedackers et al., 2007). A number of different mechanisms including direct interactions between p65 and ER (Quaedackers et al., 2007), cofactor recruitment (Harnish et al., 2000; Speir et al., 2000) and E2-mediated modulation of IκBα levels (Sun et al., 1998) have been suggested to explain these results. Direct interactions between ERα and p65 have been shown in osteoblastic U2-OS cells (Quaedackers et al., 2007) although E2 prevents degradation of IκBα by PMA treatment of HeLa cells (Sun et al., 1998). The cofactors CBP and p300 are reported to mediate interactions between NFκB and ER in human liver and coronary smooth muscle cells, respectively (Harnish et al., 2000; Speir et al., 2000). Mutual inhibition of NFκB and ER signalling has also been detailed in an in-vivo mouse model of cardiovascular disease (Evans et al., 2001). In a reproductive context, Feldman et al. (2007) have shown...
that IL-1β inhibits ERE activity in Ishikawa cells in the presence of E2 after a 48 h treatment period and have suggested that there is also a reciprocal inhibitory action of E2 on NFκB activity. In addition, it has also been reported that NFκB activation reduces the response of both Ishikawa and endometrial stromal cells to E2 (Guzeloglu-Kayisli et al., 2008). In our current study, we did not find any effect of IL-1β on ERE activity in Ishikawa cells in the absence or presence of E2 at a 24 h time point. These results are in contrast to the additive interaction that occurs between the ER and NFκB pathways in TERT-EECs, suggesting that the relationship between these two signalling pathways is cell-type specific. This may be reflective of differences between cells derived from the healthy endometrial epithelium and those derived from adenocarcinomas or the stromal compartment and highlights the importance of using untransformed cells to model normal endometrial cell function.

Positive interactions between the ER and NFκB signalling pathways have been described in some cell lines. For example, Frasor et al. (2008) reported that E2 and TNFα or IL-1β act in synergy to up-regulate PGES expression in the MCF-7 breast cancer cell line by an ER- and NFκB-dependent mechanism, which involves increased recruitment of both ERα and p65 to the ERE in the PGES promoter. In the present study, we demonstrated that expression of PGES was markedly up-regulated when TERT-EEC were incubated with E2 and IL-1β, suggesting that p65 recruitment to the ERE may also occur in our in-vitro model. Alternatively interactions between NFκB and ER may be mediated via one of the mechanisms that have been documented to occur when there is a negative interaction between these signalling pathways (as detailed above). Further studies are necessary to determine the molecular basis for the interaction between the ER and NFκB pathways in TERT-EECs. The human prolactin promoter contains a functional ERE and is synergistically activated by E2 and TNFα in a reporter assay via an ER-dependent mechanism (Adamson et al., 2008). Endogenous prolactin gene expression was also increased synergistically by E2 and TNFα in that study. However, a reporter assay using a consensus ERE-construct showed that TNFα inhibited ERE activity in this case suggesting that the synergistic interaction between TNFα and ER is specific to the prolactin promoter (Adamson et al., 2008).

We found evidence of an additive interaction between E2 and IL-1β regulated expression of PGES and c-myc, but the same treatment did not have a similar impact on expression of PR or cyclin D1 in TERT-EEC. We suggest that these differences are due to the presence of different response elements in the promoter region of each gene. In this context, previous studies have suggested that promoter elements

**Figure 5** Regulation of endogenous gene expression by E2 and IL-1β in TERT-EECs.

Cells were treated with E2, IL-1β and E2 + IL-1β (n = 3). Same letters denote statistical significance. (A) PRα, abcd: P < 0.05; fgh: P < 0.01. (B) c-myc. ade: P < 0.001; c: P < 0.01; bf: P < 0.05. (C) PGES. af: P < 0.01; b: P < 0.05; cdeghi: P < 0.001. (D) Cyclin D1. ab: P < 0.01.
within each of these genes can be regulated by NFKB (Duyao et al., 1990a, b; Guttridge et al., 1999; Takebayashi et al., 2003; Saïtoh et al., 2005; Condon et al., 2006; Ackerman et al., 2008) but that their regulation by E2 is more complex. Notably, ligand-activated ERs can regulate gene expression directly via an ERE or indirectly by interacting with other transcription factors including AP-1 and Sp1 (Gruber et al., 2004). ER-dependent regulation of PR is reported to be mediated by both ERs and a Sp1 site (Chauchereau et al., 1991; Petz et al., 2004). Although c-myc is considered to be an E2-regulated early response gene, its promoter does not contain a consensus ERE but its E2 responsiveness is reported to be mediated via Sp1 binding (Dubik and Shiu, 1992). The PGES promoter is reported to contain a functional ERE upstream of the transcription start site (Frasor et al., 2008) although the responsiveness of cyclin D1 to E2 is reported to involve AP-1, Sp1 and NFKB sites rather than a consensus ERE (Castro-Rivera et al., 2001; Rubio et al., 2006).

A positive interaction between the ER- and NFKB-signalling pathways has also been reported to occur at kB sites. In the T47D breast cancer cell line, E2 induces proliferation and cyclin D1 expression by an NFKB dependent mechanism, which is enhanced in the presence of TNFα and involves the formation of a protein complex containing ER, p65 and the coactivator RAC3 (Rubio et al., 2006). In COS-1 cells, ERα and NFKB have also been found to have a synergistic action at the S-HT1A receptor promoter via NFKB sites, although this study also showed that E2 represses the activity of an NFKB response element in a synthetic construct, again suggesting that the interaction between the pathways is promoter specific (Wissink et al., 2001). In contrast, in our current study, we have not found any evidence for a positive or negative effect of E2 on NFKB reporter activity in TERT-EECs (data not shown).

During the putative implantation window, immunoexpression studies have revealed that ERβ is the predominant ER protein present in the nuclei of glandular and surface epithelial cells in the functional layer of the endometrium (Crichtley et al., 2002; Bombaill et al., 2008). In the present study, we detected immunoexpression of the NFKB proteins, p65 and p50, in the glandular epithelium in endometrium along with the inhibitor protein, IκBα. Our previous studies have also demonstrated the presence of mRNA for the upstream kinases MEKK1, NIK, IKKα and IKKβ in endometrium with MEKK1 and IKKα proteins localized to the glandular and, in some cases luminal, epithelium (King et al., 2001). The expression of p65 and p50 has previously been reported to peak around the putative implantation window (Laird et al., 2000; Page et al., 2002) on the basis of semi-quantitative immunohistochemical studies. Our current quantitative analysis of p65 and p105 mRNA expression in well characterized endometrial biopsies is in agreement. It should be noted that these quantitative PCR studies do not provide information regarding which cellular compartment(s) are responsible for the increased expression of p65 and p105 mRNA in the secretory phase. Leukocyte populations present in endometrium vary across the menstrual cycle (Bulmer et al., 1991) and may contribute to the changes we have documented. In any case, our current data, along with that previously reported by others, suggest that the NFKB pathway may be involved in the regulation of inflammatory events at implantation.

The IL-1 system is a key cytokine network that has an impact on endometrial cell function at the time of implantation (Simon et al., 1997; Fazleabas et al., 2004). Notably, IL-1 is produced by the preimplantation embryo (Baranao et al., 1997) and the IL-1 receptor type I is present in endometrial epithelium (Bigonnesse et al., 2001). An IL-1 receptor antagonist has been shown to prevent implantation in mice (Simon et al., 1994) although a further study did not report a similar effect (Abbondanzo et al., 1996). Our data suggest that IL-1 may augment the actions of E2 on the endometrial epithelium in vivo. This could be a mechanism to allow the developing blastocyst to modulate the function of the endometrial epithelium enhancing the likelihood of successful implantation (Fig. 6). For example, both cyclo-oxygenase and PGES enzymes are present in the human endometrial epithelium during the implantation window (Jones et al., 1997; Marions and Danielsson, 1999; Milne et al., 2001). Prostaglandins increase vascular permeability, modulate decidualization and regulate the immune response at implantation (Tranguch et al., 2005; Kennedy et al., 2007). Our data suggest that E2 and IL-1β may act additively to increase the production of PGE2 by up-regulating PGES expression in the endometrial epithelium. We recognize that progesterone may also impact the ER and NFKB signalling pathways at implantation. However, the endometrial epithelium does not express the PR during the implantation window, so progesterone actions would be mediated via the stromal compartment (Wang et al., 1998). Although the TERT-EECs do express the PR, examination of progesterone effects in our in-vitro epithelial cell model would not be representative of the environment in vivo.

In summary, we have identified a novel positive interaction between the ER- and NFKB-dependent signalling pathways in an endometrial epithelial cell line derived from healthy endometrium. NFKB activation modulates ERE activity by an ER and NFKB dependent mechanism and can enhance ER-mediated endogenous gene expression in an in-vitro human endometrial epithelial cell model. The positive interaction
between NFκB and ER may be involved in the regulation of epithelial cell function at implantation and aberrant interactions between these signalling pathways may be involved in pathologies such as early pregnancy failure and infertility.

**Supplementary data**
Supplementary data are available at http://humrep.oxfordjournals.org/.

**Authors’ Roles**

**Acknowledgements**
We thank our research nurses Catherine Murray, Catherine Cairns and Sharon MacPherson for patient recruitment and assistance with biopsy collection, Pamela Brown for preparation of viral constructs, Amirah Mohamed for technical assistance and Ronnie Grant for graphical assistance.

**Funding**
This research was supported by the Caledonian Research Foundation (personal research fellowship to Dr Anne King), the Barbour Watson Fund and Tenvous, Scotland. PTKS and FC were supported by MRC programme U.1276.00.002.00005.01. HODC was supported by MRC programme grant G0500047.

**References**


Critchley HO, Henderson TA, Kelly RW, Scobie GS, Evans LR, Groome NP, Saunders PT. Wild-type estrogen receptor (ERbeta1) and the splice variant (ERbetaex/beta2) are both expressed within the human endometrium throughout the normal menstrual cycle. *J Clin Endocrinol Metab* 2002; **87**:5265–5273.


Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. *Endocrinology* 1999; **140**:5566–5578.


